Author Contributions: Mr Fournier had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Fournier, DeRubeis, Hollon, Dimidjian, Amsterdam, Shelton, Fawcett.
Acquisition of data: Fournier, DeRubeis, Hollon, Dimidjian, Amsterdam, Shelton, Fawcett.
Analysis and interpretation of data: Fournier, DeRubeis, Hollon, Dimidjian, Amsterdam, Shelton, Fawcett.
Drafting of the manuscript: Fournier, DeRubeis, Hollon.
Critical revision of the manuscript for important intellectual content: Fournier, DeRubeis, Hollon, Dimidjian, Amsterdam, Shelton, Fawcett.
Statistical analysis: Fournier, DeRubeis.
Obtained funding: DeRubeis, Hollon, Amsterdam.
Administrative, technical, or material support: Fournier, DeRubeis, Hollon, Dimidjian, Amsterdam, Shelton, Fawcett.
Financial Disclosures: Dr Amsterdam reported serving on the speakers' bureau of Wyeth Pharmaceuticals and Bristol Myers Squibb; receiving research support from Novartis, Eli Lilly, Sanofi, Cephalon, and Forest Laboratories; and serving as a consultant for Bristol Myers Squibb. Dr Shelton reported serving as a consultant to AstraZeneca, Eli Lilly, Evotec, Forest Pharmaceuticals, Gideon Richter, Janssen Pharmaceuticals, Merck, Novartis Pharmaceuticals, Ostuka Pharmaceuticals, Pamlab, Pfizer, Repligen, Sierra Neuropharmaceuticals, and Wyeth; receiving speaking honoraria from AstraZeneca, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Pamlab, Pfizer, and Wyeth; and receiving research and/or grant support from Bristol Myers Squibb, Eli Lilly, Evotec, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Ostuka Pharmaceuticals, Pamlab, Pfizer, Repligen, and Wyeth. Dr Fawcett reported serving as a consultant to Abbott Laboratories, Merck, and Slack; receiving speaking honoraria from Eli Lilly; and serving as a board member for the Berman Center and on the scientific advisory boards for the nonprofit advocacy organizations NARSAD and the Depression and Bipolar Support Alliance. Dr Fawcett also reported providing expert testimony on cases involving pharmaceutical companies including Banner Health and Alphapharm and currently chairing the Mood Disorders Work Group for the forthcoming revision of the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition). No other disclosures were reported.
Funding/Support: This research was supported by grants MH50129 (R10), MH55875 (R10), MH01697 (K02), MH01741 (K24), and MH060998 (R01) from the National Institute of Mental Health, Bethesda, Maryland.
Role of the Sponsor: The funding sources had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Additional Contributions: We thank the authors who shared their data with us for this project, with special thanks to Marieke Wichers, PhD, Maastricht University, School for Mental Health and Neuroscience; John Cornell, PhD, University of Texas Health Science Center; and Karl-O. Hiller, PhD, Steiner Arzneimittel, for providing us with the raw data from their respective studies. Finally, we thank all those who responded to our inquiries, even if data from their studies could not be made available. None were compensated for their contributions.